1. ¹Myeloma Institute for Research and Therapy, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA
2. ²ZymoGenetics Inc., Seattle, WA, USA

Correspondence: Dr S Yaccoby, Myeloma Institute for Research and Therapy, Department of Internal Medicine, University of Arkansas for Medical Sciences, 4301 W. Markham, Slot 776, Little Rock, AR 72205, USA. E-mail: yaccobyshmuel@uams.edu

Received 23 August 2007; Revised 23 October 2007; Accepted 2 November 2007; Published online 29 November 2007.

Abstract

APRIL (a proliferation-inducing Ligand) and BLyS/BAFF (B-lymphocyte stimulator/B-cell-activating factor of the TNF (tumor necrosis factor) family have been shown to be the survival factors for certain myeloma cells in vitro. BAFF binds to the TNF-related receptors such as B-cell maturation antigen (BCMA), transmembrane activator and CAML interactor (TACI) and BAFFR, whereas APRIL binds to TACI and BCMA and to heparan sulfate proteoglycans (HSPG) such as syndecan-1. TACI gene expression in myeloma reportedly can distinguish tumors with a signature of microenvironment dependence (TACI^high) versus a plasmablastic signature (TACI^low). We tested the effect of atacicept (formerly TACI-Ig, which blocks APRIL and BAFF) and BAFFR-Ig (which blocks BAFF only) on primary myeloma growth in the SCID-hu model and in coculture with osteoclasts. With only few exceptions, atacicept and to a lesser extent BAFFR-Ig, inhibited growth of TACI^high but not TACI^low myeloma samples in vivo and ex vivo, and the response rate was inversely correlated with TACI expression. Most TACI^high myeloma cells were molecularly classified as being low risk with our recently described 70-gene model. APRIL and BAFF were highly expressed by osteoclasts and were upregulated in myeloma cells after coculture with osteoclasts. Our findings suggest that APRIL plays an essential role in the survival of TACI^high bone marrow-dependent myeloma cells and TACI gene expression may be a useful predictive marker for patients who could benefit from atacicept treatment.